Dare Bioscience, Inc. current report, 07 July 2022

Business Context and Reporting Period

Daré Bioscience, Inc. (DARE) filed this Form 8-K on July 7, 2022, to report a significant non-dilutive funding event. The company is a biotechnology firm focused on developing long-acting reversible contraceptives, specifically the DARE-LARC1 program.

Key Financial Metrics

  • Grant Payment Received: Approximately $7.96 million received on July 7, 2022.
  • Total Funding Received to Date: Approximately $19.41 million under the Grant Agreement as of July 7, 2022.
  • Total Potential Grant Value: Up to $48.95 million.
  • Funding Source: Bill & Melinda Gates Foundation.
  • Grant Period: June 30, 2021, to November 1, 2026.
  • Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for these metrics as this is a current report on a specific event, not a periodic financial statement.

Material Changes

The primary material change is the receipt of the $7.96 million grant payment, increasing the total non-dilutive funding received under the June 30, 2021 agreement to $19.41 million. This funding supports technology development and preclinical activities for the DARE-LARC1 program.

Outlook, Risks, and Contingencies

  • Contingent Payments: Additional payments under the Grant Agreement are contingent upon the DARE-LARC1 program achieving specified development and reporting milestones during the Grant Period.
  • Management Commentary: The filing confirms the funds are designated for nonclinical proof of principle studies.
  • Risks: Future funding is not guaranteed and depends on milestone achievement.

Investor Verification Checklist

  • Verify the specific development and reporting milestones required to unlock the remaining potential funding of approximately $29.54 million.
  • Confirm the timeline for the next scheduled milestone review or payment.
  • Review the company's latest 10-Q or 10-K to assess how this $7.96 million cash inflow impacts overall liquidity and cash burn rates.
  • Monitor progress on the DARE-LARC1 nonclinical proof of principle studies.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.